2026-04-13T02:06:07Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/127822025-10-24T10:24:57Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Heemann, Uwe author Bengtsson, Mats author Binet, Isabelle author Böhmig, Georg author FURIAN, LUCREZIA author Bestard, Oriol author 2025-03-18T12:29:13Z 2025-03-18T12:29:13Z 2025-01 HLA incompatible; Desensitization; Kidney transplantation HLA incompatible; Desensibilització; Trasplantament renal HLA incompatible; Desensibilización; Trasplante renal Highly sensitized (HS) patients in need of kidney transplantation (KTx) typically spend a longer time waiting for compatible kidneys, are unlikely to receive an organ offer, and are at increased risk of antibody-mediated rejection (AMR). Desensitization using imlifidase, which is more rapid and removes total body immunoglobulin G (IgG) to a greater extent than other methods, enables transplantation to occur between HLA-incompatible (HLAi) donor–recipient pairs and allows patients to have greater access to KTx. However, when the project was launched there was limited data and clinical experience with desensitization in general and with imlifidase specifically. Hence, this Delphi methodology was used to reach a consensus from a multi-disciplinary team (MDT) of experts from 15 countries on the management of HS patients undergoing imlifidase HLAi from a deceased donor (DD) KTx. This Delphi consensus provides clinical practice guidance on the use of imlifidase in the end-to-end management of HS patients undergoing an HLAi DD KTx and supports centers in the development of guidelines for the utilization and integration of imlifidase into clinical practice. The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors declare that this study received funding from Hansa Biopharma for the development of this project. The funder had the following involvement with the study: logistic support for the project meetings and contracting services of an independent medical education agency to support the medical writing. http://hdl.handle.net/11351/12782 Ronyons - Trasplantació Rebuig (Biologia) Immunosupressió Antígens HLA Decisió de grup Immunoglobulina G ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Surgical Procedures, Operative::Transplantation::Organ Transplantation::Surgical Procedures, Operative::Kidney Transplantation PHENOMENA AND PROCESSES::Immune System Phenomena::Transplantation Immunology::Host vs Graft Reaction::Graft Rejection ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunosuppression::Desensitization, Immunologic PSYCHIATRY AND PSYCHOLOGY::Behavior and Behavior Mechanisms::Psychology, Social::Group Processes::Consensus CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Immunoglobulin Isotypes::Immunoglobulin G CHEMICALS AND DRUGS::Biological Factors::Antigens::Antigens, Surface::Histocompatibility Antigens::HLA Antigens TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::intervenciones quirúrgicas::trasplante::trasplante de órganos::intervenciones quirúrgicas::trasplante de riñón FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::inmunología del trasplante::reacción huésped contra injerto::rechazo del injerto TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunosupresión::desensibilización inmunológica PSIQUIATRÍA Y PSICOLOGÍA::conducta y mecanismos de la conducta::psicología social::procesos de grupo::consenso COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::isotipos de inmunoglobulinas::inmunoglobulina G COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::antígenos::antígenos de superficie::antígenos de histocompatibilidad::antígenos HLA Desensitization With Imlifidase for HLA-Incompatible Deceased Donor Kidney Transplantation: A Delphi International Expert Consensus